Back to search

Peptide record

TPDB04449

C7A-Δ C7A Antibacterial Anticancer standard

27 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB04449

Peptide_Name

C7A-Δ C7A

Activity

Antibacterial Anticancer

Activity_category_statistics

Anti-infective peptides Cancer-related peptides

Database_Source

AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 27-aa standard natural multi-activity (Antibacterial and Anticancer) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

KILRGVAKKIMRTFLRRISKDILTGKK-NH2

FASTA

>TPDB04449|Antibacterial;Anticancer|length=27
KILRGVAKKIMRTFLRRISKDILTGKK-NH2

Formula C143H261N45O33S1

Absent Amino Acids NCEQHPWY

Common Amino Acids K

Mass 3170.99

PI 12.43

Basic Residues 10

Acidic Residues 1

Hydrophobic Residues 11

Net Charge +9

Boman Index 6.46

Hydrophobicity -0.289

Aliphatic Index 115.56

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 3

number

Amino Acid Distribution

A: 1 R: 4 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 4 L: 3 K: 6 M: 1 F: 1 P: 0 S: 1 T: 2 W: 0 Y: 0 V: 1

Length

Formula

C143H261N45O33S1

Mass

3170.99

12.43

Net Charge

Boman Index

6.46

Hydrophobicity

-0.289

C_terminal_Modification

Amidation

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial Antitumor

Origin

Synthetic peptide NK-2 peptide based derivatives

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =10.6 ± 0.4 µM

Detail Source Activity Anticancer

Activity Measurement 10.6

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 30-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =13.0 ± 1.0 µM

Detail Source Activity Anticancer

Activity Measurement 13.0

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 2-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =12.1 ± 1.6 µM

Detail Source Activity Anticancer

Activity Measurement 12.1

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =37 ± 4.3 µM

Detail Source Activity Anticancer

Activity Measurement 37

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 5 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >50 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 6 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 12.5µM approx.

Detail Source Activity Anticancer

Activity Measurement >50 % at 12.5µM approx.

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 7 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >60% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >60 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC24

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 8 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >60% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >60 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC24

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 9 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >60% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >60 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC40

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 10 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >50 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC40

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 11 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >50 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC60

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 12 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >50 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC60

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 13 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >60% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >60 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC32

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 14 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability =50% at 12.5µM approx.

Detail Source Activity Anticancer

Target

Cancer Type Colorectal Cancer

Cell Line HROC32

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 15 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >40% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >40 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 16 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >50 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 17 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >55% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >55 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC18

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 18 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >75% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >75 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC18

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 19 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >55% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >55 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC24

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 20 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >70% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >70 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC24

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 21 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >45% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >45 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC40

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 22 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >85% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >85 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC40

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 23 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >70% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >70 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC60

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 24 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >70% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >70 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC60

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 25 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >80% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >80 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC113

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 26 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >70% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >70 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC113

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 27 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >55% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >55 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC32

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 28 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >85% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >85 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC32

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 29 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >50 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC107

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 30 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >70% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >70 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC107

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014